Effect of Bevacizumab on Refractory Meningiomas: 3D Volumetric Growth Rate Versus Response Assessment in Neuro-oncology Criteria

Overview

Journal Neurooncol Adv

Publisher Oxford University Press

Date 2024 Oct 30

PMID 39474492

Authors

Sara Faye Borenstein

Ruth Eliahou

Alexandra Amiel

Alisa Talianski

Jonathan Ofer

Shaked Even-Haim

Andrew Kanner

Yosef Laviv

Dror Limon

Tali Siegal

Shlomit Yust-Katz

Affiliations

Soon will be listed here.

Abstract

Background: Meningiomas are the most common primary tumor in the central nervous system. About 15%-20% are aggressive and tend to recur and progress despite conventional treatment. Bevacizumab has been found to be effective in the treatment of refractory meningiomas in retrospective studies. The Response Assessment in Neuro-Oncology (RANO) criteria are widely used to assess the effect of treatment. Recent studies suggest that the 3D volumetric growth rate (3DVGR) may be more accurate for irregularly shaped tumors. The aim of this study was to compare these approaches.

Methods: Twenty patients with refractory meningiomas were treated with bevacizumab. Tumors were measured using the RANO criteria and 3DVGR before and after initiation of treatment by 2 radiologists using PACS and BRAIN LAB iPLAN software, respectively, findings were compared.

Results: A total of 46 lesions were included in the final analysis. Bevacizumab was shown to be effective by both assessment methods. According to RANO criteria, the rate of progression-free survival at 6 months was 47%. According to 3DVGR, all lesions were characterized by either a decrease in volume or stable growth after treatment initiation. A decrease in 3DVGR of 50% or more was found in 90% of lesions. In several patients, there were discordances between RANO criteria and 3DVGR.

Conclusions: Although RANO criteria are widely accepted for evaluation of response to treatment of meningiomas, 3DVGR seems to generate more precise measurements of irregularly shaped tumors. The results of this study offer important evidence that bevacizumab may be beneficial in treating refractory meningiomas.

References

Peyre M, Zanello M, Mokhtari K, Boch A, Capelle L, Carpentier A . Patterns of relapse and growth kinetics of surgery- and radiation-refractory meningiomas. J Neurooncol. 2015; 123(1):151-60. DOI: 10.1007/s11060-015-1778-1. View

Gillespie C, Richardson G, Mustafa M, Taweel B, Bakhsh A, Kumar S . Volumetric Growth and Growth Curve Analysis of Residual Intracranial Meningioma. Neurosurgery. 2023; 92(4):734-744. PMC: 9988310. DOI: 10.1227/neu.0000000000002268. View

Dasanu C, Alvarez-Argote J, Limonadi F, Codreanu I . Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs. Expert Opin Biol Ther. 2018; 19(2):99-104. DOI: 10.1080/14712598.2019.1559292. View

Furtner J, Schopf V, Seystahl K, Le Rhun E, Ruda R, Roelcke U . Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. Neuro Oncol. 2015; 18(3):401-7. PMC: 4767240. DOI: 10.1093/neuonc/nov183. View

Maggio I, Franceschi E, Tosoni A, Di Nunno V, Gatto L, Lodi R . Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. CNS Oncol. 2021; 10(2):CNS72. PMC: 8162186. DOI: 10.2217/cns-2021-0003. View

Gritsch S, Batchelor T, Gonzalez Castro L . Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. Cancer. 2021; 128(1):47-58. DOI: 10.1002/cncr.33918. View

Ostrom Q, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol. 2019; 21(Suppl 5):v1-v100. PMC: 6823730. DOI: 10.1093/neuonc/noz150. View

Le Van T, Graillon T, Jacob J, Vauleon E, Feuvret L, Boch A . Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort. J Neurooncol. 2021; 153(1):55-64. DOI: 10.1007/s11060-021-03741-7. View

Huang R, Bi W, Weller M, Kaley T, Blakeley J, Dunn I . Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2018; 21(1):26-36. PMC: 6303427. DOI: 10.1093/neuonc/noy137. View

10.

Graillon T, Ferrer L, Siffre J, Sanson M, Peyre M, Peyriere H . Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study. Neuro Oncol. 2021; 23(7):1139-1147. PMC: 8661407. DOI: 10.1093/neuonc/noab019. View

11.

Franke A, Skelton Iv W, Woody L, Bregy A, Shah A, Vakharia K . Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review. Surg Neurol Int. 2018; 9:133. PMC: 6057170. DOI: 10.4103/sni.sni_264_17. View

12.

Alexiou G, Gogou P, Markoula S, Kyritsis A . Management of meningiomas. Clin Neurol Neurosurg. 2010; 112(3):177-82. DOI: 10.1016/j.clineuro.2009.12.011. View

13.

Norden A, Drappatz J, Wen P . Advances in meningioma therapy. Curr Neurol Neurosci Rep. 2009; 9(3):231-40. DOI: 10.1007/s11910-009-0034-5. View

14.

Kumthekar P, Grimm S, Aleman R, Chamberlain M, Schiff D, Wen P . A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma. Neurooncol Adv. 2022; 4(1):vdac123. PMC: 9549880. DOI: 10.1093/noajnl/vdac123. View

15.

Huang R, Unadkat P, Bi W, George E, Preusser M, McCracken J . Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression. Neuro Oncol. 2018; 21(2):234-241. PMC: 6374755. DOI: 10.1093/neuonc/noy126. View

16.

Scerrati A, Mongardi L, Visani J, Lofrese G, Cavallo M, Fiorentino A . The controversial role of Bevacizumab in the treatment of patients with intracranial meningioma: a comprehensive literature review. Expert Rev Anticancer Ther. 2020; 20(3):197-203. DOI: 10.1080/14737140.2020.1736567. View

17.

Kidd A, Anderson O, Cowell G, Weir A, Voisey J, Evison M . Fully automated volumetric measurement of malignant pleural mesothelioma by deep learning AI: validation and comparison with modified RECIST response criteria. Thorax. 2022; 77(12):1251-1259. PMC: 9685726. DOI: 10.1136/thoraxjnl-2021-217808. View

18.

Garcia J, Hurwitz H, Sandler A, Miles D, Coleman R, Deurloo R . Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020; 86:102017. DOI: 10.1016/j.ctrv.2020.102017. View

19.

Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyriere H . Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial. Clin Cancer Res. 2020; 26(3):552-557. DOI: 10.1158/1078-0432.CCR-19-2109. View

20.

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View